Savara Inc.
NASDAQ:SVRABiotechnology
+$0.03 today
- Market cap
- $1.04B
- Beta
- 0.27
- P/E (TTM)
- -10.6
- EPS (TTM)
- -$0.51
Volume 5.51M
Average 1.53M
SVRA Inventory
Raw materials, work in progress, and finished goods held for sale.
Savara Inc.NASDAQ: SVRA
Inventory · Q1 FY2026 · quarter ended Mar 2026
Inventory remains negative
Q1 FY2026 inventory was $0, compared with $0 a year earlier.
Context
- Inventory amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Inventory increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Inventory history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 2.05M | +279.5% |
| FY2021 | 2021-12-31 | (1.14M) | — |
Inventory vs competitors
How SVRA compares with its peers on the latest reported figures
- SVRA's Mar 2026 inventory of $0 is the highest of the 2 companies compared; the peer median is $0.
- Inventory amounts to 0.0% of total assets for SVRA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding SVRA) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34.01M | 52.1M | 26.59M | 15.13M | 33.18M |
| Short-term Investments | 127.16M | 73.78M | 135.73M | 181.2M | 202.52M |
| Net Receivables | 1.14M | 954K | 1.01M | 1.04M | 1.25M |
| Inventory | (1.14M) | 2.05M | 0 | 0 | 0 |
| Other Current Assets | 1.5M | (1.98M) | 280K | 455K | 1.29M |
| Total Current Assets | 165M | 128.95M | 165.95M | 202.14M | 241.62M |
| Property, Plant & Equipment (Net) | 73K | 51K | 270K | 165K | 100K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 11.27M | 10.66M | 10.96M | 10.34M | 11.64M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 251K | 116K | 387K | 242K | 84K |
| Total Non-current Assets | 11.6M | 10.82M | 11.62M | 10.74M | 11.82M |
| Total Assets | 176.6M | 139.78M | 177.56M | 212.88M | 253.44M |
| Account Payables | 1.44M | 1.33M | 3.5M | 4.55M | 5.76M |
| Short-term Debt | 8.33M | 0 | 0 | 0 | 7K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 4.05M | 5.02M | 8.08M |
| Total Current Liabilities | 14.66M | 5.87M | 10.6M | 14.72M | 20.4M |
| Long-term Debt | 17.32M | 26.08M | 26.35M | 26.62M | 29.91M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 117K | 54K | 247K | 87K | 0 |
| Total Non-current Liabilities | 17.44M | 26.13M | 26.6M | 26.71M | 29.91M |
| Total Liabilities | 32.1M | 32M | 37.19M | 41.43M | 50.3M |
| Common Stock | 116K | 116K | 140K | 173K | 204K |
| Retained Earnings | (300.52M) | (338.67M) | (393.37M) | (489.25M) | (608.09M) |
| Accumulated OCI | 5K | (605K) | (271K) | (750K) | (87K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 144.5M | 107.78M | 140.37M | 171.45M | 203.13M |
| Total Debt | 25.79M | 26.14M | 26.49M | 26.74M | 29.91M |
| Net Debt | (8.22M) | (25.96M) | (94K) | 11.61M | (3.27M) |
Savara Inc.
NASDAQ:SVRA
Intrinsic Alpha fair value
Locked
Current Price
$4.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.